Secretory Phospholipase A2 and Lipoprotein-Associated Phospholipase A2 as Biomarkers of Cardiovascular Disease and Therapeutic Targets

Authors

  • Alexandros D Tselepis Dpt of Biochemistry-Clinical Chemistry, University of Ioannina, Ioannina, Greece

DOI:

https://doi.org/10.2015/hc.v5i1%20Sup.368

Abstract

Atherosclerosis is not only a lipid-driven disease but it is an intricate process that also involves the simultaneous and combined effect of inflammatory and immunological factors. A substantial body of peer-reviewed studies has validated the cardiovascular risk predictive value of a variety of inflammatory markers including two members of the phospholipase A2 (PLA2) superfamily, the type IIA secretory PLA2 (sPLA2) and the lipoprotein-associated phospholipase A2 (Lp-PLA2). In animal, pathological and epidemiological studies, the increased levels of these two PLA2 have been related to an increase in complex coronary artery lesions and an increase in major cardiovascular clinical events. Therefore, inhibition of these enzymes has become the focus of research in the last decennium. Novel pharmacological inhibitors of those enzymes emerge as promising therapeutical options for treating patients with coronary artery disease.... (excerpt)

Author Biography

Alexandros D Tselepis, Dpt of Biochemistry-Clinical Chemistry, University of Ioannina, Ioannina, Greece

Specialty: Cardiology

Downloads

Issue

Section

Athens Cardiology Update 2010